Mid Atlantic Bio Angels Forms Closed-End Investing Pool Seeking New Biotech Investment Opportunities


NEW YORK, June 17, 2016 (GLOBE NEWSWIRE) -- Mid Atlantic Bio Angels (MABA) announces today that it has formed a closed-end investment pool (Pool) funded solely by current, active MABA members.  The Pool is intended to enable these members to diversify their portfolios by collectively making more frequent, and smaller investments in a greater number of companies.

“Over the last few years we presented our members with many exciting opportunities,” said Yaniv Sneor, a MABA co-founder and president of Blue Cactus Consulting, “However, our current process has resulted in only a few investments. While high selectivity is not unusual among our peers in the early stage biotech angel and venture capital communities, we decided to look for ways to increase the number of investments that our members could make through MABA on an annual basis, even if those investments are smaller.”

Investment decisions will be based solely on the vote of the Pool contributors, who will also conduct the due diligence on each investment opportunity. 

Steve Goodman, another MABA co-founder, and an attorney at Pryor Cashman in NYC elaborates further: “Offering even a small amount of money to some of these companies at an early stage can serve as validation for their proposed business and begin a longer term relationship. It also incentivizes MABA members to assist them as they progress and hit their milestones, and encourages them to return to us for additional funding in future investment rounds.”

MABA anticipates the Pool to be fully invested within two years, and expects that members will then collaborate to create a larger Pool.

About Mid Atlantic Bio Angels
Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA's goal is to create an environment where the depth of investors' knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.


            

Contact Data